Embedded Files
Psychedelic Education Alliance for Knowledge
Our Mission
Our Mission
Psychedelic Literacy for Modern Systems
Psychedelic Literacy for Modern Systems
As psychedelic research, public use, and policy reform accelerate, multiple systems, healthcare, education, emergency services, and community wellbeing, are encountering these substances faster than formal regulation or training frameworks can respond.
PEAK delivers evidence-based psychedelic literacy for medical professionals, educators, first responders, and the public. Our programs focus on foundational understanding: mechanisms of action, psychological effects, risks and contraindications, harm reduction, ethical considerations, and post-experience integration.
This work is not about promoting use or training specialists. It is about preparedness, equipping individuals and institutions with the knowledge needed to respond responsibly, reduce harm, and support mental health in a world where altered states are increasingly present.
Education is the missing infrastructure. PEAK exists to build it.
The Challenge
The Challenge
Psychedelics are already present across healthcare, education, and public systems, but training has not kept pace.
Psychedelics are already present across healthcare, education, and public systems, but training has not kept pace.
Across systems, the same gaps appear:
Across systems, the same gaps appear:
Rising use outside clinical settings
Uncertainty around legality, ethics, and professional scope
No standardized protocols or risk frameworks
Little to no formal education in medical, psychology, or public health training
Growing demand for integration, triage, and harm-reduction support
Without education, systems are forced into reactive positions. Preparedness, not crisis response, is the missing infrastructure.
Our Solution
Our Solution
PEAK delivers evidence-based psychedelic literacy through workshops, lectures, and custom education for healthcare, education, and public systems.
PEAK delivers evidence-based psychedelic literacy through workshops, lectures, and custom education for healthcare, education, and public systems.
Our offerings include:
Short-form workshops and keynote lectures
Custom education for healthcare, education, and public-facing organizations
University curriculum licensing and guest teaching
Harm-reduction, risk awareness, and ethical decision-making frameworks
Research, policy, and clinical updates translated into accessible language
Psychedelics are already here. Education must catch up.
Psychedelics are already here. Education must catch up.
WHY PEAK
WHY PEAK
Clinical Expertise
Clinical Expertise
Evidence-Based, Non-Ideological Approach
Evidence-Based, Non-Ideological Approach
Advanced Educational Design
Advanced Educational Design
Interdisciplinary & Scalable
Interdisciplinary & Scalable
PEAK’s medical leadership includes licensed Nurse Practitioners currently advancing into Psychiatric NP specialization, ensuring all education aligns with real-world clinical standards and hospital needs.
Our curriculum is grounded in current research, clinical data, and emerging policy—not hype. We translate psychedelic science into practical, safe, medically relevant training.
Founded by a curriculum specialist with 20+ years in health and wellness education, corporate training, and MS.Ed graduate research in psychedelics, PEAK builds learning tools that professionals trust and can immediately apply.
PEAK connects neuroscience, psychology, medicine, and policy—then delivers it through scalable licensing models for universities, hospitals, and global health systems.
PEAK translates psychedelic research into real-world understanding
PEAK translates psychedelic research into real-world understanding
HOW WE WORK WITH PARTNERS
HOW WE WORK WITH PARTNERS
For Hospitals
For Hospitals
Annual subscription licensing
Custom departmental workshops
A full psychedelic education suite for clinical staff
Quarterly update briefs (policy, research, safety protocols)
Education Sector
Education Sector
Workshops for parents, teachers and students in secondary education
Multi-year curriculum license
Custom lecture packages
Guest lecturer series
Undergraduate + graduate versions, high school possible
Faculty training support
Conferences
Conferences
Keynotes
Breakout sessions
Workshops
Specialized panels
Corporate & Industry
Corporate & Industry
Corporate HR and L&D teams w/annual renewals
Government and civic education, first responders
Psychedelic education for executive staff
Public Health Departments
The Team
The Team
Anna Farkas M.S. Ed
Anna Farkas M.S. Ed
Founder
Educationalist, Researcher and Speaker
Vilma Farkas FNP - BC & Ilona Farkas AG-ACNP BC
Vilma Farkas FNP - BC & Ilona Farkas AG-ACNP BC
Subject Matter Experts, Board certified Nurse Practitioners
For Investors
For Investors
Why Now?
Why Now?
The global psychedelic therapeutics market is rapidly expanding.
The global psychedelic therapeutics market is rapidly expanding.
The psychedelic therapeutics market is projected to grow from $3.6 billion in 2023 to $8.3 billion by 2032, driven by clinical research and shifting regulation. (1)
Investment in psychedelic companies surged in recent years
Investment in psychedelic companies surged in recent years
Private investment in psychedelic medicine companies exceeded $2 billion between 2020 and 2022, reflecting rapid sector development and institutional interest. (2)
Clinical evidence continues to validate therapeutic potential
Clinical evidence continues to validate therapeutic potential
A Phase 3 trial of MDMA-assisted therapy for PTSD showed that 67% of participants no longer met diagnostic criteria after treatment. (3)
Psychedelic use is increasing among adults
Psychedelic use is increasing among adults
Hallucinogen use among U.S. adults aged 26+ has more than doubled since 2015. (4)
Global mental health demand is outpacing clinical capacity.
Global mental health demand is outpacing clinical capacity.
Nearly 1 in 8 people worldwide live with a mental health disorder, while treatment access remains limited. (5)
Why PEAK is a high-growth opportunity
Why PEAK is a high-growth opportunity
Massive market expansion ahead (US, Europe, Australia)
Psychedelics moving toward medical mainstream
Zero standardized training in medical school → enormous unmet need
Regulatory tailwinds
CME/CE potential
Licensing = high-margin recurring revenue
Built for global scalability
First-mover advantage in a soon-to-be billion-dollar education category
Questions?
Questions?
Contact PEAKforEducation@gmail.com for more information on the project
References:
References:
Fortune Business Insights. (2023). Psychedelic drugs market size, share & trends analysis report, 2023–2032. https://www.fortunebusinessinsights.com.
Psychedelic Alpha. (2023). Psychedelics industry financing report. https://psychedelicalpha.com
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., et al. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled Phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (NSDUH). https://www.samhsa.gov
World Health Organization. (2022). World mental health report: Transforming mental health for all. World Health Organization. https://www.who.int
Page updated
Google Sites
Report abuse